- Home
- RELX vs RVPHW Comparison
RELX vs RVPHW Comparison
Compare RELX & RVPHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RELX
- RVPHW
- Stock Information
- Founded
- RELX 1903
- RVPHW 2018
- Country
- RELX United Kingdom
- RVPHW United States
- Employees
- RELX N/A
- RVPHW 14
- Industry
- RELX Business Services
- RVPHW Biotechnology: Pharmaceutical Preparations
- Sector
- RELX Consumer Discretionary
- RVPHW Health Care
- Exchange
- RELX Nasdaq
- RVPHW Nasdaq
- Market Cap
- RELX 97.3B
- RVPHW N/A
- IPO Year
- RELX N/A
- RVPHW N/A
- Fundamental
- Price
- RELX $53.89
- RVPHW $0.04
- Analyst Decision
- RELX Strong Buy
- RVPHW
- Analyst Count
- RELX 2
- RVPHW 0
- Target Price
- RELX N/A
- RVPHW N/A
- AVG Volume (30 Days)
- RELX 851.0K
- RVPHW 22.4K
- Earning Date
- RELX 07-25-2025
- RVPHW 03-14-2025
- Dividend Yield
- RELX 1.12%
- RVPHW N/A
- EPS Growth
- RELX 10.15
- RVPHW N/A
- EPS
- RELX 1.29
- RVPHW N/A
- Revenue
- RELX $11,810,658,884.00
- RVPHW N/A
- Revenue This Year
- RELX $9.12
- RVPHW N/A
- Revenue Next Year
- RELX $7.22
- RVPHW N/A
- P/E Ratio
- RELX $40.78
- RVPHW N/A
- Revenue Growth
- RELX 2.98
- RVPHW N/A
- 52 Week Low
- RELX $43.45
- RVPHW $0.13
- 52 Week High
- RELX $56.33
- RVPHW $0.15
- Technical
- Relative Strength Index (RSI)
- RELX 53.46
- RVPHW N/A
- Support Level
- RELX $52.11
- RVPHW N/A
- Resistance Level
- RELX $54.30
- RVPHW N/A
- Average True Range (ATR)
- RELX 0.50
- RVPHW 0.00
- MACD
- RELX 0.08
- RVPHW 0.00
- Stochastic Oscillator
- RELX 78.76
- RVPHW 0.00
About RELX RELX PLC PLC
RELX is a global provider of information-based analytics and decision tools for professional and business customers in various industries. The company serves sectors such as science and medical research, risk management, and legal. In addition, RELX organizes large-scale digital and face-to-face events such as industry trade shows. Around 60% of revenue is generated in North America and about 20% in Europe.
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.